Dongsheng Tu
机构: Professor of Biostatistics, Queen's University at Kingston, Canada
每年引用次数
引用次数
引用: 50,542
H-指数: 84
I10-指数 : 235
出版物: 544
Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18
Natasha B Leighl , Luis Paz-Ares , Jean-Yves Douillard , Christian Peschel
Journal of Clinical Oncology 23 ( 12) 2831 -2839
141
2005
A Bartlett-type correction for the subject-years method in comparing survival data to a standard population
Dongsheng Tu , Alan J. Gross
Statistics & Probability Letters 29 ( 2) 149 -157
3
1996
Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial.
Elisa Fontana , Gift Nyamundanda , David Cunningham , Dongsheng Tu
JCO precision oncology 4 ( 4) 1152 -1162
1
2020
RSF1 and Not Cyclin D1 Gene Amplification May Predict Lack of Benefit from Adjuvant Tamoxifen in High-Risk Pre-Menopausal Women in the MA.12 Randomized Clinical Trial
Dana Keilty , Marguerite Buchanan , Katerina Ntapolias , Olga Aleynikova
PLoS ONE 8 ( 12) e81740
9
2013
Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer
Rachel A. Goodwin , Rahima Jamal , Dongsheng Tu , Wendy Walsh
Gynecologic Oncology 131 ( 2) 315 -320
12
2013
Can Administrative Data Improve the Performance of Cancer Clinical Trial Economic Analyses
Timothy P. Hanna , Paul Nguyen , Joseph Pater , Christopher J. O’Callaghan
Journal of Oncology Practice 15 ( 9)
3
2019
RAO'S SCORE TESTS IN SURVIVAL ANALYSIS: EXAMPLES AND BARTLETT TYPE ADJUSTMENTS
Dongsheng Tu
Communications in Statistics-theory and Methods 30 1521 -1532
1
2001
Abstract CT131: A randomized (RCT) phase II study of oncolytic reovirus (pelareorep ) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC)
Vanessa Bernstein , Susan Ellard , Susan F. Dent , Karen A. Gelmon
Cancer Research 77
2
2017
A generalized partially linear mean-covariance regression model for longitudinal proportional data, with applications to the analysis of quality of life data from cancer clinical trials.
Xueying Zheng , Guoyou Qin , Dongsheng Tu
Statistics in Medicine 36 ( 12) 1884 -1894
6
2017
A single-index threshold Cox proportional hazard model for identifying a treatment-sensitive subset based on multiple biomarkers.
Ye He , Huazhen Lin , Dongsheng Tu
Statistics in Medicine 37 ( 23) 3267 -3279
3
2018
Quantile regression and empirical likelihood for the analysis of longitudinal data with monotone missing responses due to dropout, with applications to quality of life measurements from clinical trials.
Yang Lv , Guoyou Qin , Zhongyi Zhu , Dongsheng Tu
Statistics in Medicine 38 ( 16) 2972 -2991
1
2019
A bootstrap semiparametric homogeneity test for the distributions of multigroup proportional data, with applications to analysis of quality of life outcomes in clinical trials.
Chunlin Wang , Dongsheng Tu
Statistics in Medicine 39 ( 12) 1715 -1731
2020
Update on the Colon Health and Life-Long Exercise Change Trial: A Phase III Study of the Impact of an Exercise Program on Disease-Free Survival in Colon Cancer Survivors
Kerry S. Courneya , Janette Vardy , Sharlene Gill , Derek Jonker
Current Colorectal Cancer Reports 10 ( 3) 321 -328
25
2014
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
James N. Ingle , Dongsheng Tu , Joseph L. Pater , Silvana Martino
Breast Cancer Research and Treatment 99 ( 3) 295 -300
80
2006
Quality of Life Analyses in a Clinical Trial of DPPE (tesmilifene) Plus Doxorubicin Versus Doxorubicin in Patients with Advanced or Metastatic Breast Cancer: NCIC CTG Trial MA.19
Jianhua Liu , Dongsheng Tu , Janet Dancey , Leonard Reyno
Breast Cancer Research and Treatment 100 ( 3) 263 -271
24
2006
Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example.
Joseph Pater , Dongsheng Tu , Lois Shepherd , James N. Ingle
Breast Cancer Research and Treatment 108 ( 2) 265 -269
7
2008
An Evaluation of Linked Administrative Data for Cancer Clinical Trial Economic Analysis
Timothy P Hanna , Paul Nguyen , Joe Pater , Christopher J O’Callaghan
International Journal for Population Data Science 5 ( 5)
2020
Inference on the probability P(T1<T2) as a measurement of treatment effect under a density ratio model and random censoring
Shan Jiang , Dongsheng Tu
Computational Statistics & Data Analysis 56 ( 5) 1069 -1078
6
2012
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study
Eric X. Chen , Derek J. Jonker , Jonathan M. Loree , Hagen F. Kennecke
JAMA Oncology 6 ( 6) 831 -838
32
2020
Final results of OV16, a phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel (CP) versus CP in first-line chemotherapy for advanced epithelial ovarian cancer (EOC): A GCIG study of NCIC CTG, EORTC-GCG, and GEICO.
Andres Cervantes-Ruiperez , Paul Hoskins , Ignace Vergote , Elizabeth A. Eisenhauer
Journal of Clinical Oncology 31 5502 -5502
3
2013
Lois Shepherd Lesley Seymour Kathleen I. Pritchard C Karapetis John Zalcberg Jeremy Shapiro Timothy Price Christopher J O'Callaghan Michael Brundage Wendy R. Parulekar Ian Gilron John Goffin Lillian Siu Ronald R. Holden Nancy E Davidson Penelope Bradbury Stephen KL Chia Zee Chung-Ying Benny Ming Tsao Sharlene Gill